Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

VOLUME 4 , ISSUE 3 ( July-September, 2010 ) > List of Articles


Ultrasonic Characterization of Adnexal Masses

Ulrich Honemeyer, Sanja Kupesic Plavsic

Keywords : Adnexal mass,3D power Doppler,Tumor neoangiogenesis,3D rendering,Ovarian cancer

Citation Information : Honemeyer U, Plavsic SK. Ultrasonic Characterization of Adnexal Masses. Donald School J Ultrasound Obstet Gynecol 2010; 4 (3):275-297.

DOI: 10.5005/jp-journals-10009-1149

License: CC BY-NC 4.0

Published Online: 01-06-2011

Copyright Statement:  Copyright © 2010; The Author(s).


Adnexal masses have an etiological spectrum ranging from gynecologic to non-gynecologic causes. Because they can be benign or malignant, their evaluation has to include a careful analysis of the patients history, a physical examination, and laboratory and imaging tests. Transvaginal ultrasonography remains the standard for evaluation of adnexal masses. Findings suggestive of malignancy in an adnexal mass include a solid component or intracystic proliferations, thick septations (greater than 2 to 3 mm), bilateral occurrence, blood flow within the solid component of the mass, and presence of ascites. Tumor-neoangiogenesis has typical features of flow pattern and vascular architecture, indicative of malignancy, which can be visualized by Doppler ultrasound. Power Doppler with its increased sensitivity for slow flow and small vessels is ideal for this purpose and, in combination with acquisition of a volume data set of the region of interest (RoI), gives new insights in tumor angiology and appears to be an additional diagnostic tool. An important predictor of malignancy is a resistance index (RI) below 0.42 in arterial tumor vessels. 3D rendering modes like magic cut, NICHE mode, power Doppler glass body rendering, can make valuable contributions to differential diagnose of adnexal masses. A variety of adnexal masses is illustrated in their specific sonographic appearance, with special regard to ovarian carcinoma.

PDF Share
  1. Diagnosis and management of adnexal masses. Am Fam Physician. 2009 Oct 15;80(8):815-20.
  2. Relative frequency of primary ovarian neoplasms: A ten year review. Obstet Gynecol 1989;74:921-26.
  3. Initial evaluation and referral guidelines for management of pelvic/ ovarian masses. J Obstet Gynaecol Can. 2009;31(7):668-80.
  4. US characterization of ovarian masses: A meta-analysis. Radiology 2000;217: 803-11.
  5. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: Results of a multicenter European study. Journal Ultrasound Med 2002;21:1105-11.
  6. Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models. Ultrasound Obstet Gynecol 2002;20(6):597-604.
  7. The vascular morphology of tumors. In Peterson HI (Ed): Tumor Blood Circulation: Angiogenesis, vascular morphology and blood flow of experimental human tumors. Boca Raton, FL: CRC Press, 1979:1-47.
  8. The significance of hyperemia around tumor implants. Am J Pathol 1946;22:821-26.
  9. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73-85.
  10. Growth and metastasis of tumor in organ culture. Tumor Res 1963;16:453-67.
  11. Tumor behaviour in isolated perfused organs: In vitro growth and metastasis of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164:491-502.
  12. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-88.
  13. Regulators of angiogenesis. Annu Rev Physiol 1991;53:217.
  14. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1989;82:4-6.
  15. Angiogenesis-inducing factors: A review. In: Pick E (Ed): Limphokines, London: Academic Press,1981;4:69-88.
  16. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti- Cancer Drugs 1995;6:3-18.
  17. From angiogenesis to lymphangiogenesis. Nature Med 2001;7(2):151-52.
  18. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med 1997;3:1222-27.
  19. Intratumoral microvessel density and p53 correlation with metastasis in headand- neck squamous-cell carcinoma. Int J Cancer 1993;55: 739-44.
  20. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
  21. Tumor angiogenesis: Review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302-313.
  22. Angiogenic factors. Science 1987;2345:442-47.
  23. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-039.
  24. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48.
  25. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-44.
  26. Expression of VEGF in ovarian epithelial tumors. J Soc Gynecol Investig 2001; 8(1)(Suppl):766.
  27. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003;9(6):677-84.
  28. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1 alpha/VP16 hybrid transcription factor. Circulation 2000;102(18):2255-61.
  29. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007;28(1):20-47.
  30. Growth and metastasis of tumor in organ culture. Cancer 1963;16:453-57.
  31. Extracellular compartments of solid tumors. In Becker J (Ed): Cancer. New York: Plenum Press, 1975:327.
  32. Determination of tumor blood flow: A review. Cancer Res 988; 48:2641-46.
  33. The assessment of ovarian tumor angiogenesis by three-dimensional power Doppler. In Kurjak A (Ed): Three-dimensional Power Doppler in Obstetrics & Gynecology. The Parthenon Publishing Group, 2000.
  34. Tumor blood flow characterization, modifications and role in hyperthermia. Trans Sonics Ultrasonics 1984;31:504-09.
  35. Blood flow oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989;49:6449.
  36. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146(5):1029-39.
  37. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4(6): 915-24.
  38. Sonographic depiction of tumor vascularity and flow: From in vivo models to clinical applications. J Ultrasound Med 2000;19:55-61.
  39. Parameters and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 1996;86:353-54.
  40. Preoperative diagnosis of primary fallopian tube carcinoma. Gynecol Oncol 1998;68:29-34.
  41. A combined Doppler and morphopathological study of ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1997;71:147-50.
  42. Differences in the angiogenesis of benign and malignant ovarian tumors, demonstrated by analyses of color Doppler ultrasound, immunohistochemistry, and microvessel density. Cancer 1997;80:899-907.
  43. 3D Color Power Angio TM imaging: A new method to assess intracervical vascularization in benign and pathological conditions. Ultrasound Obstet Gynecol 1998;2:133-38.
  44. Three-dimensional ultrasound and power Doppler in assessment of uterine and ovarian angiogenesis: A prospective study. Croat Med J 1999;40:413-20.
  45. Transvaginal colour flow imaging: A possible new screening technique for ovarian cancer. Br Med J 1989;299:1367-70.
  46. Transvaginal color Doppler of the assessment of pelvic circulation. 1989;68:131-36.
  47. Assessment of ovarian tumor vascularity with transvaginal color Doppler sonography. J Ultrasound Med 1991;10:563-68.
  48. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991;10: 295-97.
  49. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992;79:159-62.
  50. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol 1992;80:917-21.
  51. Transvaginal color Doppler sonography of adnexal masses: Differences in blood flow impedance in benign and malignant lesions. Am J Roentgenol 1993;160:1225-28.
  52. Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow Doppler. Obstet Gynecol 1994;83:125-130.
  53. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol 1995;172:1496-1500.
  54. A combined Doppler and morphopathological study of ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1997;71:147-150.
  55. Sonography of ovarian masses: Poor sensitivity of resistive index for identifying malignant lesions. Am J Roentgenol 1994;162:1355-59.
  56. Transvaginal color Doppler and pelvic tumor angiogenesis: Lessons learned and future challenges. Ultrasound Obstet Gynecol 1995;6:145-59.
  57. Transvaginal color Doppler sonography in the assessment of pelvic tumor vascularity. Ultrasound Obstet Gynecol 1993;3:137-54.
  58. Ovarian masses: Can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology 1994;190:333-36.
  59. Differentiation of benign and malignant adnexal masses: Relative value of gray-scale, color Doppler, and spectral Doppler sonography. Am J Roentgenol 1995;164:381-86.
  60. Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Am J Obstet Gynecol 1996;174:101-06.
  61. Power Doppler US: A potentially useful alternative to mean frequencybased color Doppler US. Radiology 1994;190:853-56.
  62. Fractional moving blood volume: Estimation with power Doppler US. Radiology 1995;197:183-90.
  63. Power Doppler sonography. J Ultrasound Med 1996;15:164.
  64. Power Doppler ultrasound: A potential useful alternative in diagnosing pelvic pathological conditions. Clin Exp Obstet Gynecol 1996;23:229-32.
  65. Harmonic imaging with ultrasound contrast agents. Clin Radiol 1996;51:50-55.
  66. Quantification of tumor vascularity and flow with amplitude color Doppler sonography in an experimental mode: Preliminary results. J Ultrasound Med 1996;15:827.
  67. Quantified color Doppler sonography of tumor vascularity in an animal model. J Ultrasound Med 1999;18:547.
  68. Three-dimensional ultrasound evaluation of ovarian masses. Gynecol Oncol 1995;59:129-35.
  69. Three-dimensional transvaginal ultrasound in gynecological diagnosis. Ultrasound Obstet Gynecol 1999; 14:81-86.
  70. Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses? Gynecol Oncol. 2007;106(1):153-59.
  71. Adnexal mass vascularity assessed by 3-dimensional power Doppler: Does it add to the Risk of Malignancy Index in prediction of ovarian malignancy? International Journal of Gynecological Cancer 2009;19(5):867-72.
  72. Preoperative diagnosis of ovarian malignancy: Preliminary results of the use of 3-dimensional vascular ultrasound. Int J Gynecol Cancer 2009;19(3):354-60.
  73. Evaluation of adnexal masses using three-dimensional ultrasonographic technology: Preliminary report. J Ultrasound Med 1997;16:349-54.
  74. Ultrasound assessment of ovarian tumors: Comparison between transvaginal 3D technique and conventional 2 dimensional vaginal ultrasonography. Ultraschall Med 1997;18(1):26-30.
  75. Three-dimensional ultrasound: Accuracy of distance and volume measurements. Ultrasound Obstet Gynecol 1996;7:429-34.
  76. Can 3-dimensional Ultrasound change gynecological ultrasonographic examination? Donald School Journal of Ultrasound in Obstet/Gynecol 2009;3(1):6-8.
  77. Three-dimensional sonography of cystic ovarian tumors. In: Merz E (Ed). 3D ultrasonography and gynecology. Lippincott Williams & Wilkins, Philadelphia 1998.
  78. Ovarian lesions assessed by threedimensional ultrasound and power Doppler. In: Kurjak A, Kupesic S (Eds). Clinical application of 3D sonography. The Parthenon Publishing Group 2000.
  79. Preoperative diagnosis of the primary Fallopian tube carcinoma by three-dimensional static and power Doppler sonography. Ultrasound Obstet Gynecol 2000;15:246-51.
  80. Three-dimensional ultrasound and power Doppler improve the diagnosis of ovarian lesions. Gynecol Oncol 2000;76:28-32.
  81. Vascular imaging with a three dimensional power Doppler system. Am J Roentgenol 1995;165:665-68.
  82. The assessment of ovarian tumor angiogenesis: What does threedimensional power Doppler add? Ultrasound Obstet Gynecol 1998;12:136-46.
  83. Tissue block ultrasound and ovarian cancer-a pictorial presentation of findings. Donald School Journal of Ultrasound in Obstetrics and Gynecology 2009;3(1):41-47.
  84. Three- dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000;16:365-71.
  85. Tumor vascularization Doppler measurements and chaos: What to do? Ultrasound Obstet Gynecol 1995;5:209-10.
  86. Transvaginal Doppler assesses ovarian flow. Diagn Imag 1998;9:47.
  87. 3D transvaginal color Doppler sonography: Current and potential applications. Med Imag Int 1999;9:10-13.
  88. Threedimensional power Doppler sonography: Imaging and quantifying blood flow and vascularization. Ultrasound Obstet Gynecol 1999;14:139-43.
  89. 3D PD imaging of ovarian pathology- Advantages and limitation of the method: How can we standardize the results? Donald School Journal of Ultrasound in Obstetrics and Gynecology 2009;3(1):48-54.
  90. Contrast agents in diagnostic ultrasound. Ultrasound Med Biol 1989;15:319-33.
  91. Color amplitude imaging: Preliminary results using vascular sonographic agents. J Ultrasound Med 1990;15:127-34.
  92. Contrast enhanced three-dimensional power Doppler sonography for the differentiation of adnexal masses. Obstet Gynecol 2000;96:452-58.
  93. Ultrasound methods to distinguish between malignant and benign adnexal masses in the hands of examiners with different levels of experience. Ultrasound Obstet Gynecol 2009;34:454-61.
  94. Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet Gynecol 2009;34:462-70.
  95. Which parameters could be useful for predicting malignancy in solid adnexal masses? Donald School Journal of Ultrasound in Obstetrics and Gynecology 2009;3(1): 1-5.
  96. Preoperative evaluation of pelvic tumors by Doppler and three-dimensional sonography. J Ultrasound Med 2001;20:829-40.
  97. Risk of malignancy in sonographically confirmed septated cystic ovarian tumors. Gynecol Oncol 2010 Jun 14 (Pub Med ahead of publication).
  98. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (London) 1997;390:404-07.
  99. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995;1:149-53.
  100. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;7:58-62.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.